Angiotensin II type 1 receptor blockers as a first choice in patients with acute myocardial infarction
Jang Hoon Lee, Myung Hwan Bae, Dong Heon Yang, Hun Sik Park, Yongkeun Cho, Won Kee Lee, Myung Ho Jeong, Young Jo Kim, Myeong Chan Cho, Chong Jin Kim, Shung Chull Chae, Korea Acute Myocardial Infarction Registry Investigators
Korean J Intern Med. 2016;31(2):267-276.   Published online 2015 Dec 23     DOI:
Citations to this article as recorded by Crossref logo
Angiotensin II Type 1 Receptor Blocker, Fimasartan, Reduces Vascular Smooth Muscle Cell Senescence by Inhibiting the CYR61 Signaling Pathway
Inho Kim, Chan Soon Park, Hae-Young Lee
Korean Circulation Journal.2019; 49(7): 615.     CrossRef
Comparative Effectiveness of Combination Therapy with Statins and Angiotensin-Converting Enzyme Inhibitors versus Angiotensin II Receptor Blockers in Patients with Coronary Heart Disease: A Nationwide Population-Based Cohort Study in Korea
Jimin Lee, Sukhyang Lee
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy.2018; 38(11): 1095.     CrossRef
24-Hour blood pressure response to lower dose (30 mg) fimasartan in Korean patients with mild to moderate essential hypertension
Hae-Young Lee, Cheol-Ho Kim, Jae-Kwan Song, Shung Chull Chae, Myung Ho Jeong, Dong-Soo Kim, Byung-Hee Oh
The Korean Journal of Internal Medicine.2017; 32(6): 1025.     CrossRef
Angiotensin converting enzyme inhibitors remain the first treatment of choice
Pyung Chun Oh, Ichiro Sakuma, Toshio Hayashi, Kwang Kon Koh
The Korean Journal of Internal Medicine.2016; 31(2): 237.     CrossRef